Updated on 14 March 2013
Generating value from pipeline of early stage assets
The company has a number of new projects in various stages of development. In the coming six months, it will be assessing a range of options to fund some or all of these programs through to clinical trials. Assets that fall into this category are Oligonucleotide portfolio; Orbital; PXS4728 ¡V; LOX / LOXL2 Inhibitor Program; and PXS64/PXS25.
Mr Phillips concluded: "I look forward to reporting on the outcomes of discussions with the FDA and the results from the bronchiectasis trial in coming months. Further updates on the initiatives outlined above will be provided as matters progress. I am confident that we have both the team and resources to successfully navigate the challenges facing the company."
Mr Philips has been appointed to the Pharmaxis board of directors effective March 14, 2013. The company is in the process of finalising details of his appointment terms which will be disclosed to the market when concluded.